A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
First received: June 1, 2007
Last updated: NA
Last verified: June 2007
History: No changes posted

A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo.

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: MK0359
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Study Start Date: December 2002

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • You are between the ages of 40 and 75
  • You have had a history for at least a year of COPD symptoms
  • You have a history of smoking one pack of cigarettes per day for 10 years

Exclusion Criteria:

  • You have been in a research study with an investigational drug or vaccine in the last 4 weeks.
  • You have donated blood in the last 4 weeks.
  • You have been hospitalized or had major surgery in the last 4 weeks
  • You have been treated in the emergency room within the last 2 months or hospitalized within the last 3 months for your COPD symptoms
  • You have a history of heart problems in the last 6 months
  • You have a history of stomach problems
  • You are unwilling to avoid grapefruit juice throughout the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00482235

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00482235     History of Changes
Other Study ID Numbers: 2007_569
Study First Received: June 1, 2007
Last Updated: June 1, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 15, 2014